MPM BioImpact’s iTeos Therapeutics ITOS Stock Holding History

MPM BioImpact’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,745,943	Closed	-$10.4M	–	48
2025 Q1	$10.4M	Hold	1,745,943	–	–	1.79%	23
2024 Q4	$13.4M	Hold	1,745,943	–	–	1.9%	21
2024 Q3	$17.8M	Hold	1,745,943	–	–	2.67%	12
2024 Q2	$25.9M	Hold	1,745,943	–	–	4.03%	4
2024 Q1	$23.8M	Hold	1,745,943	–	–	3.83%	5
2023 Q4	$19.1M	Hold	1,745,943	–	–	4.47%	5
2023 Q3	$19.1M	Hold	1,745,943	–	–	5.1%	5
2023 Q2	$23.1M	Hold	1,745,943	–	–	4.65%	6
2023 Q1	$23.8M	Hold	1,745,943	–	–	6.17%	4
2022 Q4	$34.1M	Hold	1,745,943	–	–	8.85%	2
2022 Q3	$33.3M	Hold	1,745,943	–	–	7.88%	2
2022 Q2	$36M	Hold	1,745,943	–	–	9.99%	2
2022 Q1	$56.2M	Sell	1,745,943 -98,784	-5%	-$3.59M	15.08%	2
2021 Q4	$85.9M	Sell	1,844,727 -262,365	-12%	-$8.73M	15.66%	2
2021 Q3	$56.9M	Sell	2,107,092 -231,489	-10%	-$6.05M	8.82%	2
2021 Q2	$60M	Sell	2,338,581 -16,976	-0.7%	-$404K	9.85%	2
2021 Q1	$80.5M	Hold	2,355,557	–	–	10.12%	3
2020 Q4	$79.7M	Hold	2,355,557	–	–	13.99%	3
2020 Q3	$58.1M	Buy	+2,355,557	New	+$63.4M	14%	4

Other funds holding ITOS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MPM BioImpact's ITOS Position: Q2 2025 in Review

MPM BioImpact sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 1,745,943 shares — an estimated $10.4M sold.

MPM BioImpact first reported a position in ITOS in Q3 2020 and held it in 19 quarters. The position peaked at $85.9M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

MPM BioImpact reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
MPM BioImpact sold 1,745,943 iTeos Therapeutics shares in Q2 2025, an estimated $10.4M.
MPM BioImpact first reported a position in iTeos Therapeutics in Q3 2020 and held it in 19 quarters.
MPM BioImpact's iTeos Therapeutics position peaked at $85.9M in Q4 2021.
137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.